
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, DC 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)
June 9, 2016**

IRIDEX CORPORATION
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

0-27598
(Commission
File Number)

77-0210467
(IRS Employer
Identification No.)

**1212 Terra Bella Avenue
Mountain View, California 94043**
(Address of principal executive offices, including zip code)

(650) 940-4700
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01 Regulation FD Disclosure.

On June 9, 2016, William M. Moore, the Chief Executive Officer of IRIDEX Corporation, will participate in the Singular Research Spring Select San Francisco Conference, at which Mr. Moore will present the attached presentation slides.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Presentation slides at the Singular Research Spring Select San Francisco Conference held on June 9, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IRIDEX CORPORATION

By: /s/ WILLIAM M. MOORE
William M. Moore
President and Chief Executive Officer

Date: June 9, 2016

EXHIBIT INDEX

Exhibit
No.

Description

99.1

Presentation slides at the Singular Research Spring Select San Francisco Conference held on June 9, 2016.



IRIDEX Corporation

June 9, 2016

Singular Research Conference – San Francisco, CA

NASDAQ: IRIX



Safe Harbor

Participation in this presentation requires that you be aware of the Federal legislation regarding forward-looking statements. Accordingly, during the course of this presentation we may make forward-looking statements regarding future events or the future performance of the Company.

We caution you that such statements are just predictions that involve risks and uncertainties, and that actual events or results could differ materially. We discuss a number of the risks in our business in detail in the Company's SEC reports, including our latest [Form 10-K](#) and our latest [Form 10-Q](#).



IRIDEX Corporation

Future Growth and Revenue

 **MicroPulse®**

New
Technologies

 **CYCLO G6™**
Glaucoma Laser System


New
Business
Model



New
Growth
Trajectory



Business
Priorities





Growing Elderly Populations



 **343M**

people worldwide with age-related, vision-threatening retinal disease by 2021

+

Additional retinal indications




65M

people with glaucoma, 17 million diagnosed

+

High cost and sustainability of pharmacotherapy





Transitioning to High Growth

An Evolving Business to Compelling New Opportunities



▲
Legacy




▲
Premium Proprietary




▲
Scalable Platform
Razor/Razorblade


Retina Business ▶



Traditional




Pre-treatment




1 Year Post-treatment

Scarring clearly visible using traditional laser technology and continuous-wave laser treatment.

uP MicroPulse®



Pre-treatment



1 Year Post-treatment

Scarring non-existent with equivalent visual acuity results as traditional laser, plus increased retinal sensitivity, using MicroPulse laser therapy.

Clinical Evidence


Safety

10-year follow-up data proved no detectable retina damage.



Efficacy

Control randomized trials showed improved vision and improved retinal sensitivity.



Efficiency

More treatable patients. Improved patient pass-through rates.




Economics


IQ 577™ and TxCell™ nearly paid for itself in less than a year. Using anti-VEGF and MicroPulse may reduce treatment burden and costs.



Targeted Market Segment

Understanding Retina Market breakdown and opportunity





Glaucoma Global Macro Trends



65M


Estimated 65 million patients worldwide, 17 m diagnosed

70+

Aging population demographic - 50% of glaucoma patients are above 70


50%

Compliance is the issue - 50% of patients stop taking meds at 1 year





Targeted Market Segment: 5M Patients on Multiple Glaucoma Meds Represent \$2B Opportunity



# Treatments/year*	2
Average Probe Price	\$200
Number of Patients	5 M
TAM	\$2 B



Data from the Focused US Rollout

Future Growth and Revenue



- 300 ASCs control 50% of glaucoma surgical volume [of which 47 are IRIDEX customers]
- 5,000 ASCs perform eye surgery
- 19,000 Ophthalmologists



Cyclo G6: The New Solution

Innovative Glaucoma System Provides Competitive Advantage


Intelligence resides in the probe,
not the appliance

Revolutionary strategy and
technology provide inherent
competitive advantage

Growing portfolio allows treatment
of various stages along the glaucoma
continuum of care



Expanding Probe Portfolio to Grow Procedural Opportunity






Cyclo G6: Immediate Commercial Impact

G6 Laser Console and G6 Probe sales since launch

G6 Console Units



Cyclo G6 Probe Revenue



17,172

Total G6 probes shipped
since March 2015 launch

9,579



Total G6 probes shipped
in 2016

20

Countries have purchased

261

Worldwide G6 units sold
(75% in the US)



Third-Party Results in Asia/Singapore

- 33% IOP reduction at 18 months
- Significant reduction in eye pressure (IOP) in moderate and late-stage glaucoma
- Procedure can be add-on therapy as well as monotherapy

Studies in Progress

- Wills Eye:
 - Retrospective study shows 39% IOP reduction
 - Ongoing prospective study reporting 54% IOP reduction at three months
- UC San Francisco studied anatomical effects – reporting high safety profile
- Yale University study demonstrating minimal tissue disruption
- Multi-Center Retrospective: 30% IOP reduction at month three



Executing on the Vision

Legacy Hardware



Legacy Consumables



MicroPulse®



G6 Platform



Financial Snapshot

Most Recent Quarterly Results – Q1, 2016

P&L

Revenue \$11.9M

Growth Rate from Q1 FY15 11%


Balance Sheet

Cash \$10.5 MM

Debt \$0.00

2016 Guidance: Double-digit growth, accelerating in second half

Additional Financial Information



Business Model Targets

60% consumable, 40% equipment

50/50 retina and glaucoma

40/60 US and International

55+% gross margin, 15+% operating margin



Future Growth and Revenue

 **MicroPulse®**

New
Technologies

 **CYCLO G6™**
Glaucoma Laser System

New
Business
Model



New
Growth
Trajectory

Slide 5:

Global estimates of diabetes prevalence for 2013 and projections for 2035," International Diabetes Foundation, Diabetes Research and Clinical Practice, 2014;103:137-149.
Market Scope 2015 Comprehensive Global Report

Slide 6:

Market Scope 2015 Comprehensive Global Report

Slide 9:

Vujosevic S, Bottega E, Casciano M, Piliotto E, Convento E, Miden E. Retina 2010
Note: Circle denotes traditional laser burn.

Slide 10:

Luttrull JK, Sramek C, Palanker D, Spink CJ, Musch DC. Long-term safety, high-resolution imaging, and tissue temperature modeling of subvisible diode micropulse photocoagulation for retinovascular macular edema. Retina, 2012;32(2):375-86.

Lavinsky D, Cardillo JA, Melo LA Jr., Dare A, Farah ME, Belfort R Jr. Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci, 2011;52(7):4314-23.

Vujosevic S, Bottega E, Casciano M, Piliotto E, Convento E, Miden E. Microperimetry and fundus autofluorescence in diabetic macular edema: Subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. Retina, 2010;30(6):908-916.

Vujosevic S, Martini F, Longhi E, Convento E, Cavarzeran F, Miden E. Subthreshold micropulse yellow laser versus subthreshold micropulse infrared laser in center-involving diabetic macular edema: Morphologic and functional safety. Retina, 2015.

Caskey P. MicroPulse laser therapy and anti-vegf injections for macular edema associated with crvo. Retinal Physician, 2013;S1-S2.

Escaf M. MicroPulse results exceed expectations in a treatment-naïve patient with center-involving diabetic macular edema. Retinal Physician, 2015;(September)S2.

Rosenthal J, Feistmann J. Making the jump to MicroPulse laser therapy for treating the macula. Retina Today, 2015;(insert:(January/February))1-2.

Slide 11:

Market Scope 2015 Comprehensive Global Report

Slide 15:

Assumption: 2 treatments per year. Chew, P, mTSCPC vs TSCPC, 2014 reports 1.6 treatments in 18 months.

Slide 16:

Glaucoma Research Foundation
IMS Health
Market Scope 2015 Comprehensive Report on the Global Glaucoma Surgical Device Market



thank you.



Saksonov, Poster
MicroPulse 577 Cystoid
ME due to BRVO, APVRS
2011



Mahootchi, Rethinking
Regimen for Retinal
Disease, RT 2014



Saksonov, MicroPulse 577
vs Classic ME due to BRVO
AVPRS-VRSI 2011



Gossage, 532TxCell
MicroPulse ME due to
BRVO, RT 2014



Inagaki, MicroPulse for
ME due to BRVO, J Ophth
2014



Caskey 577 nm MicroPulse
CRVO, RP 2013



Wong, MicroPulse
abstract, ASRS 2014doc



Luttrull, Retinal Protective
Therapy Dry AMD, IOVS
2016



Luttrull, Laser
Resensitization AMD,
Retina 2015



Luttrull, Long-term safety
MicroPulse, Retina 2011



Parodi, Intravitreal
combined w/ grid for ME
in BRVO, BJO 2008



Luttrull, Laser for BRVO,
Retina Today 2011



Saksonov, 577 nm ARM,
RP 2011




Parodi, Subthreshold Grid
Laser 810, Ophth 2006
FRO



Video 1:
MicroPulse Technology Animation



Video 2:
Cyclo G6 Laser System Technology



Video 3:
Transscleral Cyclophotocoagulation with Cyclo G6



Video 4:
Interview with Dr. Jacky Lee at ESCRS 2015



Video 5:
Media Release on New Treatments for Glaucoma
(Chinese with English subtitles)



Video 6:
News Report Dr. Harris on IQ577 for MLT and MP3

